Alx Oncology Holdings Inc

  • Safety Score
  • Market Cap $88.91M
  • PE -1
  • Debt $10.60M
  • Cash $16.17M
  • EV $83.35M
  • FCF -$130.08M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$151.16M
EBIT-$150.40M
ROE-110%
ROA-81%
FCF-$130.08M
Equity$136.81M
Growth Stability1
PE-0.59
PB0.65
P/FCF-0.68
Price/Cash0.18
Debt/Equity0.08
Debt/FCF-0.08
Sales CAGR-0%
Equity CAGR-21%
Earnings Growth YoY-40%
Earnings Growth QoQ-22%
Sales CAGR 5Y-1%
Equity CAGR 5Y-23%
Equity CAGR 3Y-30%
Market Cap$88.91M
Assets$185.72M
Total Debt$10.60M
Cash$16.17M
Shares Outstanding51.54M
EV83.35M
Safety Score65%
Working Capital123.56M
Current Ratio4.82
Shares Growth 3y10%
Equity Growth QoQ-14%
Equity Growth YoY-19%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

SEC Filings

Direct access to Alx Oncology Holdings Inc (ALXO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Alx Oncology Holdings Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Alx Oncology Holdings Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Alx Oncology Holdings Inc Discounted Cash Flow

Fully customizable DCF calculator online for Alx Oncology Holdings Inc.

= -$1.3B
012345678910TV
fcf-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$130M-$1.3B
DCF-$118M-$108M-$98M-$89M-$81M-$73M-$67M-$61M-$55M-$50M-$502M
Value-$1.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201812/201912/202012/202112/202212/2023TTM
Net Margins-842%-485%-4K%----
ROA--180%-10%-22%-40%-66%-81%
ROE-33%-12%-23%-47%-85%-110%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--0.37---0.12-0.08-0.08
Debt over Equity--0.08--0.040.060.08
Growth Stability------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-132%-75%-100%---1%
Earnings YoY growth-34%119%64%48%30%-
Equity YoY growth-36%-709%-16%-27%-28%-23%
FCF YoY growth-5%162%79%32%45%-